Literature DB >> 15635263

Radiosensitivity of peripheral blood lymphocytes obtained from patients with cancers of the breast, head and neck or cervix as determined with a micronucleus assay.

Sadayuki Ban1, Chika Konomi, Mayumi Iwakawa, Shigeru Yamada, Tatsuya Ohno, Hiroshi Tsuji, Syuhei Noda, Yoshifumi Matui, Yoshinobu Harada, John B Cologne, Takashi Imai.   

Abstract

The in vitro radiation sensitivities of peripheral blood lymphocytes obtained from 48 normal females and 168 female cancer patients were measured with the cytokinesis-blocking micronucleus assay. Cancer patients group had significantly higher mean baseline micronucleus frequency than normal healthy controls. Breast cancer patients were more radiosensitive than normal individuals. Cervical cancer cases were less radiation sensitive than normal subjects. The relative lack of radiation sensitivity in cervical-cancer cases could be due to modification of the radiosensitivity of patients' immune-responsible cells by human papillomaviruses infection. Normal individuals and cancer patients were classified according to their radiation sensitivity which was evaluated with the radiation-induced micronucleus frequencies. Such a classification will be an important initial step to characterize the radiosensitive, radioresistant, or cancer-prone individuals using specific SNP typing.

Entities:  

Mesh:

Year:  2004        PMID: 15635263     DOI: 10.1269/jrr.45.535

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  8 in total

Review 1.  Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.

Authors:  Fatemeh Sadeghi; Marzieh Asgari; Mojdeh Matloubi; Maral Ranjbar; Nahid Karkhaneh Yousefi; Tahereh Azari; Majid Zaki-Dizaji
Journal:  Biol Proced Online       Date:  2020-10-01       Impact factor: 3.244

Review 2.  Individual response of humans to ionising radiation: governing factors and importance for radiological protection.

Authors:  K E Applegate; W Rühm; A Wojcik; M Bourguignon; A Brenner; K Hamasaki; T Imai; M Imaizumi; T Imaoka; S Kakinuma; T Kamada; N Nishimura; N Okonogi; K Ozasa; C E Rübe; A Sadakane; R Sakata; Y Shimada; K Yoshida; S Bouffler
Journal:  Radiat Environ Biophys       Date:  2020-03-07       Impact factor: 1.925

Review 3.  Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.

Authors:  F Cardinale; P Bruzzi; C Bolognesi
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

4.  Association of Inflammation-Related Gene Polymorphisms With Susceptibility and Radiotherapy Sensitivity in Head and Neck Squamous Cell Carcinoma Patients in Northeast China.

Authors:  Ying Li; Li Zhu; Hongmin Yao; Ye Zhang; Xiangyu Kong; Liping Chen; Yingqiu Song; Anna Mu; Xia Li
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

5.  Chromosomal radiosensitivity in head and neck cancer patients: evidence for genetic predisposition?

Authors:  K De Ruyck; V de Gelder; M Van Eijkeren; T Boterberg; W De Neve; A Vral; H Thierens
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

6.  Genomic instability in newborn with short telomeres.

Authors:  Jennifer Moreno-Palomo; Amadeu Creus; Ricard Marcos; Alba Hernández
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

7.  Chromosomal radiosensitivity of human immunodeficiency virus positive/negative cervical cancer patients in South Africa.

Authors:  Olivia Herd; Flavia Francies; Jeffrey Kotzen; Trudy Smith; Zwide Nxumalo; Xanthene Muller; Jacobus Slabbert; Anne Vral; Ans Baeyens
Journal:  Mol Med Rep       Date:  2015-11-05       Impact factor: 2.952

8.  Association between unintentional splenic radiation and lymphopenia and high neutrophil/lymphocyte ratio after radiotherapy in patients with esophageal cancer.

Authors:  Masakuni Sakaguchi; Toshiya Maebayashi; Takuya Aizawa; Naoya Ishibashi; Masahiro Okada
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.